| Protein Name: | Stromelysin-1 (P08254) |
|---|---|
| Gene Name: | MMP3 |
| Description: | Stromelysin-1 precursor (EC 3 4 24 17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1) (SL-1) |
| PDB ID: | 1B3D |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Atorvastatin | Risk Of Repeated Angioplasty | Reduction in cardiovascular events by pravastatin(death@ myocardial infarction@stroke@ angina@ and others); reduction in risk of repeated angioplasty [ ADR Type 2 ] | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis |
| Fluvastatin | Risk Of Repeated Angioplasty | Reduction in cardiovascular events by pravastatin(death@ myocardial infarction@stroke@ angina@ and others); reduction in risk of repeated angioplasty. [ ADR Type 2 ] | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis |
| Pravastatin | Bradycardia | Reduction in cardiovascular events by pravastatin(death@ myocardial infarction@stroke@ angina@ and others); reduction in risk of repeated angioplasty [ ADR Type 2 ] | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis |
| Simvastatin | Risk Of Repeated Angioplasty | Reduction in cardiovascular events by pravastatin(death@ myocardial infarction@stroke@ angina@ and others); reduction in risk of repeated angioplasty [ ADR Type 2 ] | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis |
This panel provides information on drug category
| Toxicity | Source |
|---|